Drugs

The Body Bean, LLC

FDA issued a warning letter to The Body Bean, LLC (Paso Robles, CA, United States) on Feb 6, 2023, citing 21 CFR 207.17 and 21 CFR 207.41. Subject: Failure to Register and List.

From the letter: “you are manufacturing a hand sanitizer for U.S. commercial distribution for which you have not registered your establishment and listed your drug product with the FDA.”

Paso Robles, CA, United StatesIssued Feb 6, 2023Posted Feb 7, 2023No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
1 finding · 1 issue type
Response due
Fifteen (15) working days of receipt
FDA asks for
5 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Registration, listing & premarket · 21 CFR 207.17(a), 21 CFR 207.41(a)Hand sanitizer was manufactured for U.S. distribution without registering the establishment or listing the drug product with FDA.
you are manufacturing a hand sanitizer for U.S. commercial distribution for which you have not registered your establishment and listed your drug product with the FDA.

What FDA requested

  • Notify FDA in writing of the specific steps taken to address the violations
  • Provide an explanation of each step being taken to prevent recurrence of violations
  • Provide copies of related documentation
  • If corrective actions cannot be completed within 15 working days, state the reason for the delay and the time within which they will be done
  • If the firm believes products are not in violation, include reasoning and supporting information

FDA Warning Letter

13 paragraphs · 1 section

Text as published on FDA.gov, retrieved Oct 17, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

Sent toFebruary 6th, 2023 RE: WL 2474
AddressedDear Mr. Sickelton

1Letter text

8 paragraphs

The United States Food and Drug Administration (FDA) has reviewed your firm’s drug registration and listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug product, The Body Bean’s Hand Sanitizer - Scented. Our review revealed that you are manufacturing a hand sanitizer for U.S. commercial distribution for which you have not registered your establishment and listed your drug product with the FDA. As such, your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below.

We note that FDA previously sent you and your firm a letter on this same subject, on October 21, 2022, notifying you of your failure to register your establishment and list your drug product. Even after such notice, the registration and listing data have not been submitted to the agency.

Under section 510(j) of the FD&C Act, and 21 CFR Part 207.17(a) and 21 CFR 207.41(a) of FDA regulations, with some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States or that are offered for import into the United States must be registered with the FDA (21 U.S.C. 360(b), (c), (d), and (i)). Every person who is required to register must, at the time of initial registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution (21 U.S.C. 360(j)(1)). You have failed to fulfill your establishment registration obligations as required under section 510 of the FD&C Act, which is prohibited under section 301(p), 21 U.S.C 360 and 331(p). In addition, your firm, The Body Bean, LLC, failed to fulfill its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). Failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a). As a result, the drug, The Body Bean’s Hand Sanitizer - Scented, is misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o).

Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.

We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.

Response requested

Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research/Office of Compliance/Office of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov for further assistance. Include the case identification numbers 2474 on all correspondence.

Sincerely, /S/ Tina Smith Director (Acting), Office of Unapproved Drugs & Labeling Compliance Office of Compliance Center for Drug Evaluation and Research U.S. Food and Drug Administration

CC: Los Angeles District Office Attn: Steven E. Porter, Jr.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Paso Robles, CA, United States
Letter posted date
Feb 7, 2023
Letter issue date
Feb 6, 2023
Addressed to
Not recorded
Inspection dates
Not recorded
Response window
15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations.
Record length
751 words · 0 recorded redactions
Published status
No published close-out
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.